In contrast, the results of the NeoSphere study showed that the pCR rate achieved in breast cancer patients was 63.2% (16), those with ER/PR-negative, HER2-positive breast cancer in a chemotherapy regimen of trastuzumab combined with docetaxel on top of a dual target of trastuzumab in NAT. This evidence concerns the gene ERBB2 and breast carcinoma.